Human CEACAM-19 Antibody Summary
Ala33-Gly157
Accession # Q7692-1
Applications
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Scientific Data
View Larger
Detection of CEACAM‑19 in HEK293 Human Cell Line Transfected with Human CEACAM-19 and eGFP by Flow Cytometry. HEK293 human embryonic kidney cell line transfected with either (A) human CEACAM-19 or (B) irrelevant protein and eGFP was stained with Mouse Anti-Human CEACAM-19 Monoclonal Antibody (Catalog # MAB9397) followed by Allophycocyanin-conjugated Anti-Mouse IgG Secondary Antibody (F0101B). Quadrant markers were set based on control antibody staining (MAB0041).Staining was performed using our Staining Membrane-associated Proteins protocol.
Reconstitution Calculator
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: CEACAM-19
Carcinoembryonic antigen-related cell adhesion molecule-19 (CEACAM-19), also known as CEA-like gene 1 (CEAL1), is a member of the CEACAM subfamily of glycoproteins in the immunoglobulin (Ig) superfamily. Mature human CEACAM-19 consists of a 125 amino acid (aa) extracellular domain, a 21 aa helical transmembrane domain, and a 122 aa cytoplasmic domain (1,2). The extracellular domain contains an Ig-like domain as well as a glycosylation site, while the cytoplasmic domain is predicted to contain at least one immunoreceptor tyrosine-based activation motif (ITAM) (3,4). The extracellular domain of human CEACAM-19 shows 71%, 72%, and 78% aa identity to mouse, rat, and bovine CEACAM-19. The CEACAM family of proteins are involved in numerous intercellular-adhesion and intracellular signaling processes including cell adhesion, cell growth, recognition and differentiation, angiogenesis, and apoptosis (5,6). CEACAM-19 expression has been identified in a wide range of tissues including prostate, uterus, fetal brain, mammary and adrenal glands, skeletal muscle, small intestine, and kidney (1). Human CEACAM-19 has been found to be overexpressed in BT-474, BT20, and T47D breast cancer cell lines as well as LNCaP prostate cancer cells, suggesting a role in tumor progression and metastasis (1,3, 7). The overexpression in breast cancer patients is associated with poor prognosis (7).
- Schorilas, A. et al. (2003) Gene 310:79.
- Estiar, M. et al. (2016) Clin Exp Med doi:10.1007/s10238-016-0442-1.
- Beauchemin, N. and Arabzadeh, A. (2013) Cancer Metastasis Rev 32 (3-4):643.
- Kuespert, K. et al. (2006) Curr Opin Cell Biol 18:565.
- Obrink, B. (1997) Curr Opin Cell Biol 9:616.
- Horst, AK. and Wagener, C. (2004) Handb Exp Pharmacol 283.
- Michaelidou, K. et al. (2013) Int J Oncol 42:1770.
Product Datasheets
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsReviews for Human CEACAM-19 Antibody
There are currently no reviews for this product. Be the first to review Human CEACAM-19 Antibody and earn rewards!
Have you used Human CEACAM-19 Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
